Company Filing History:
Years Active: 1994-1995
Title: Steve F Carroll: Innovator in Ribosome-Inactivating Proteins
Introduction
Steve F Carroll is a notable inventor based in Walnut Creek, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of ribosome-inactivating proteins (RIPs). With a total of 2 patents, Carroll's work focuses on therapeutic agents that target specific cell types for the treatment of various diseases.
Latest Patents
Carroll's latest patents include innovative methods and materials for the preparation and use of purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins. One of his inventions provides vectors comprising these polynucleotides and host cells transformed with the vectors. These RIPs and their analogs are designed for use as components of cytotoxic therapeutic agents, which can selectively eliminate targeted cell types, making them particularly useful in treating autoimmune diseases, cancer, and graft-versus-host disease.
Another significant patent involves analogs of ribosome-inactivating proteins that retain their ribosome-inactivating activity while having a cysteine available for disulfide bonding. This innovation enhances the potential of these proteins in developing immunotoxins, which are therapeutic agents aimed at specific cell types.
Career Highlights
Steve F Carroll is currently associated with Xoma Corporation, where he continues to advance his research in the field of biotechnology. His work has positioned him as a key figure in the development of targeted therapeutic agents.
Collaborations
Carroll has collaborated with notable colleagues, including Susan L Bernhard and Marc D Better, contributing to the advancement of their shared research goals.
Conclusion
Steve F Carroll's innovative work in ribosome-inactivating proteins and their applications in targeted therapies highlights his significant impact on biotechnology. His contributions continue to pave the way for advancements in the treatment of critical diseases.